<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[Topics tagged with vesalius]]></title><description><![CDATA[A list of topics that have been tagged with vesalius]]></description><link>https://board.circlewithadot.net/tags/vesalius</link><generator>RSS for Node</generator><lastBuildDate>Mon, 06 Apr 2026 01:59:00 GMT</lastBuildDate><atom:link href="https://board.circlewithadot.net/tags/vesalius.rss" rel="self" type="application/rss+xml"/><pubDate>Invalid Date</pubDate><ttl>60</ttl><item><title><![CDATA[Agenzia Nova: Salute: Vesalius-Cv, anticorpo monoclonale riduce del 31 per cento rischio primo evento cardiovascolare]]></title><description><![CDATA[Agenzia Nova: Salute: Vesalius-Cv, anticorpo monoclonale riduce del 31 per cento rischio primo evento cardiovascolare31 mar 19:59 - (Agenzia Nova) - L'anticorpo monoclonale evolocumab, aggiunto alla terapia ottimizzata per il controllo del colesterolo Ldl... (Rin)Health: Vesalius-Cv, monoclonal antibody reduces the 31% risk of first cardiovascular event.Mar 31 19:59 - (Agenzia Nova) - The monoclonal antibody evolocumab, added to the optimized therapy for controlling LDL cholesterol... (Rin)#Vesalius-Cv #first #AgenziaNova https://www.agenzianova.com/a/69cc0be765aaf0.41097962/7224219/2026-03-31/salute-vesalius-cv-anticorpo-monoclonale-riduce-del-31-per-cento-rischio-primo-evento-cardiovascolare]]></description><link>https://board.circlewithadot.net/topic/d3b9a849-6f54-4e3e-8d04-126566eb54a6/agenzia-nova-salute-vesalius-cv-anticorpo-monoclonale-riduce-del-31-per-cento-rischio-primo-evento-cardiovascolare</link><guid isPermaLink="true">https://board.circlewithadot.net/topic/d3b9a849-6f54-4e3e-8d04-126566eb54a6/agenzia-nova-salute-vesalius-cv-anticorpo-monoclonale-riduce-del-31-per-cento-rischio-primo-evento-cardiovascolare</guid><dc:creator><![CDATA[italiannews@mastodon.ozioso.online]]></dc:creator><pubDate>Invalid Date</pubDate></item><item><title><![CDATA[Agenzia Nova: Salute: Vesalius-Cv, anticorpo monoclonale riduce del 31 per cento rischio primo evento cardiovascolare (2)]]></title><description><![CDATA[Agenzia Nova: Salute: Vesalius-Cv, anticorpo monoclonale riduce del 31 per cento rischio primo evento cardiovascolare  (2)31 mar 19:59 - (Agenzia Nova) - "I risultati con evolocumab segnano un cambio di paradigma nella gestione dei pazienti diabetici a rischio... (Rin)Health: Vesalius-Cv, monoclonal antibody reduces the 31% risk of first cardiovascular event (2)Mar 31 19:59 - (Agenzia Nova) - "The results with evolocumab mark a paradigm shift in the management of diabetic patients at risk..." (Rin)#Vesalius-Cv #first #AgenziaNova https://www.agenzianova.com/a/69cc0be765a022.55298828/7224220/2026-03-31/salute-vesalius-cv-anticorpo-monoclonale-riduce-del-31-per-cento-rischio-primo-evento-cardiovascolare-2]]></description><link>https://board.circlewithadot.net/topic/a9103e2e-f4cc-4807-bba5-4ac1d338247f/agenzia-nova-salute-vesalius-cv-anticorpo-monoclonale-riduce-del-31-per-cento-rischio-primo-evento-cardiovascolare-2</link><guid isPermaLink="true">https://board.circlewithadot.net/topic/a9103e2e-f4cc-4807-bba5-4ac1d338247f/agenzia-nova-salute-vesalius-cv-anticorpo-monoclonale-riduce-del-31-per-cento-rischio-primo-evento-cardiovascolare-2</guid><dc:creator><![CDATA[italiannews@mastodon.ozioso.online]]></dc:creator><pubDate>Invalid Date</pubDate></item></channel></rss>